Dimitrios Agaliotis, MD
Hematology & Oncology · Fernandina Beach, FLNPI 1790764272
Payments from drug & device makers
Across 219 payments — averaging $123.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Karyopharm Therapeutics Inc.$3K
- Bristol Myers Squibb$3K
- GSK$2K
- Johnson & Johnson$2K
- Incyte Corporation$1K
- plus $8K from 34 others
What the payments were for
- Consulting fees$17,52565%
- Travel & lodging$6182%
- Food & beverage$8,53731%
- Education$4682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $9,443 |
| Karyopharm Therapeutics Inc. | 5 | $2,844 |
| Bristol Myers Squibb | 8 | $2,715 |
| GSK | 2 | $1,858 |
| Johnson & Johnson | 12 | $1,688 |
| Incyte Corporation | 5 | $1,101 |
| E.r. Squibb & Sons, L.L.C. | 22 | $1,057 |
| Amgen | 24 | $784 |
| Seagen Inc. | 15 | $508 |
| Novartis | 13 | $503 |
| Genentech USA, Inc. | 9 | $481 |
| Beigene, Ltd. | 1 | $450 |
| Eisai Inc. | 6 | $414 |
| Lilly USA, LLC | 14 | $299 |
| Sanofi | 4 | $277 |
| Daiichi Sankyo Inc. | 4 | $236 |
| Pfizer | 8 | $201 |
| Bayer | 3 | $199 |
| Exelixis Inc. | 4 | $177 |
| Stemline Therapeutics Inc. | 5 | $177 |
| Rigel Pharmaceuticals, Inc. | 2 | $176 |
| Adaptive Biotechnologies Corporation | 2 | $171 |
| Beone Medicines USA, Inc. | 3 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $150 |
| ADC Therapeutics America, Inc. | 1 | $122 |
| Taiho Oncology, Inc. | 1 | $120 |
| Boehringer Ingelheim | 5 | $118 |
| Merck | 5 | $111 |
| Novocure Inc. | 1 | $106 |
| Alnylam Pharmaceuticals Inc. | 5 | $99 |
| Dova Pharmaceuticals | 1 | $95 |
| Caris MPI, Inc. | 1 | $83 |
| Beigene USA, Inc. | 1 | $80 |
| Gilead(2 entities) | 2 | $45 |
| Array Biopharma Inc | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Myovant Sciences Inc. | 1 | $17 |
| Verastem, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,149 in reported general payments places this provider in the 55th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 15 | $287,514 |
| TagrissoOsimertinib Mesylate | 14 | $270,703 |
| RevlimidLenalidomide | 20 | $260,845 |
| SprycelDasatinib | 12 | $216,152 |
| JakafiRuxolitinib Phosphate | 12 | $211,918 |
| Lenalidomide | 15 | $184,795 |
| BrukinsaZanubrutinib | 12 | $181,138 |
| EliquisApixaban | 100 | $117,042 |
| XareltoRivaroxaban | 67 | $56,892 |
| Anastrozole | 51 | $1,041 |
| Ondansetron OdtOndansetron | 32 | $956 |
| Letrozole | 44 | $906 |
| Dexamethasone | 51 | $717 |
| Acyclovir | 62 | $682 |
| Prochlorperazine Maleate | 28 | $655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $503 | $287,51415 claims |
| AstraZenecaTagrisso | $9,443 | $270,70314 claims |
| Bristol Myers SquibbRevlimid | $2,715 | $260,84520 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $1,057 | $216,15212 claims |
| Incyte CorporationJakafi | $1,101 | $211,91812 claims |
| Beigene USA, Inc.Brukinsa | $80 | $181,13812 claims |
| PfizerEliquis | $201 | $117,042100 claims |
| Johnson & JohnsonXarelto | $1,688 | $56,89267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Fernandina Beach
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.